<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688685</url>
  </required_header>
  <id_info>
    <org_study_id>CAD1883-201</org_study_id>
    <nct_id>NCT03688685</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate CAD-1883 in Essential Tremor</brief_title>
  <official_title>A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults With Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadent Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadent Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study designed to evaluate the safety, tolerability and efficacy of&#xD;
      CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally&#xD;
      to adult patients with ET. Patients with the diagnosis of ET based on the Movement Disorder&#xD;
      Society (MDS) criteria with a documented severity of tremor based on the&#xD;
      clinician-administered TETRAS Performance Subscale are eligible to be enrolled in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study designed to evaluate the safety, tolerability and efficacy of&#xD;
      CAD-1883, a positive allosteric modulator (PAM) of the SK channel, administered twice daily&#xD;
      orally to adult subjects with ET. Positive modulation of the small-conductance&#xD;
      calcium-activated potassium channels (SK) present in different regions of the brain aims to&#xD;
      increase the channel sensitivity to calcium resulting in reduction in neuronal firing rate.&#xD;
      In patients with ET, improving the regularity of firing of action potentials in the&#xD;
      olivo-cerebellar network can lead to improvement in motor function.&#xD;
&#xD;
      During the Screening period, each subject will undergo full assessment including medical and&#xD;
      treatment history for ET, physical examination and other screening assessments. Patients with&#xD;
      the diagnosis of ET based on the Movement Disorder Society (MDS) criteria with a documented&#xD;
      severity of tremor based on the clinician-administered TETRAS Performance Subscale are&#xD;
      eligible to be enrolled in the study. The study consists of treatment groups receiving twice&#xD;
      daily oral dosing of CAD-1883 for a treatment period of 14 days.&#xD;
&#xD;
      This study is designed to enable the assessment of safety and tolerability of CAD-1883 in&#xD;
      patients with ET as well as the determination of early treatment effect on reducing the&#xD;
      magnitude and severity of tremor while limiting the potential risk associated with a novel&#xD;
      investigational drug.&#xD;
&#xD;
      Safety and tolerability will be monitored throughout the study duration including in-clinic&#xD;
      assessments of adverse events (AEs), serious adverse events (SAEs), vital signs, 12-lead ECG,&#xD;
      urinalysis, hematology, clinical chemistry, and CAD-1883 plasma concentration level on Days&#xD;
      1, 7, 14 and 21.&#xD;
&#xD;
      Efficacy will be evaluated using the clinician-administered TETRAS Performance Subscale as&#xD;
      well as the use of a wearable sensor in the clinic and at home.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2019</start_date>
  <completion_date type="Actual">September 24, 2019</completion_date>
  <primary_completion_date type="Actual">September 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Occurrence and Severity of Treatment Emergent AEs.</measure>
    <time_frame>Time of signed informed consent until 21 days after first treatment</time_frame>
    <description>Number of subjects who experienced TEAEs and the severity of those TEAEs.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Open-label study of CAD-1883</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAD-1883</intervention_name>
    <description>Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.</description>
    <arm_group_label>Open-label study of CAD-1883</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult subjects aged between 18 and 75 years old, inclusive, with history of tremor&#xD;
             that fulfills the diagnostic criteria of ET according to Movement Disorder Society&#xD;
             (MDS) Consensus Statement on the classification of tremors from the task force on&#xD;
             tremor of the International Parkinson and Movement Disorder Society (Bhatia, 2018).&#xD;
&#xD;
          2. Duration of ET illness since the first symptoms were noticeable of at least 3 years or&#xD;
             more prior to screening, based on the subject's self-report, with onset prior to age&#xD;
             65 years old, per the Principal Investigator's assessment during screening.&#xD;
&#xD;
          3. Except for ET, subjects must be otherwise healthy as determined by the Investigator,&#xD;
             based upon a medical evaluation including medical history, physical examination,&#xD;
             laboratory tests, and 12-lead ECG.&#xD;
&#xD;
          4. Subjects are able to understand study activities required, can give written informed&#xD;
             consent, and are willing to comply with the requirements and restrictions of the&#xD;
             study.&#xD;
&#xD;
          5. Women of childbearing potential must undertake a pregnancy test with documented&#xD;
             negative serum pregnancy test at Screening and negative urine pregnancy test result at&#xD;
             Pre-dose, Days 7 and 14 before administration of the study drug, and then at the&#xD;
             Follow-up visit (Day 21).&#xD;
&#xD;
          6. Postmenopausal women must have had ≥365 days of spontaneous amenorrhea, with&#xD;
             documented follicle-stimulating hormone (FSH) ≥38 IU/mL, prior to screening. If&#xD;
             needed, per Investigator's judgment, FSH level can be performed at Screening.&#xD;
&#xD;
          7. Surgically sterile women must have documentation of a hysterectomy, bilateral&#xD;
             ovariectomy, or bilateral tubal ligation.&#xD;
&#xD;
          8. Female subjects with reproductive potential and male subjects with reproductive&#xD;
             potential or who have female partners of reproductive potential, must agree to use two&#xD;
             effective methods of contraception from signing informed consent until 90 days after&#xD;
             the last dose of study drug. Acceptable forms of contraception include double barrier&#xD;
             (ie, condom with spermicide); surgically sterilized partner (180-day minimum); or&#xD;
             abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior or ongoing medical condition or any abnormal finding on the Screening visit&#xD;
             physical exam, ECG, laboratory testing that, in the Investigator's opinion, could&#xD;
             adversely affect the safety of the subject or the conduct of the study assessments.&#xD;
&#xD;
          2. Any neurological abnormality other than ET upon neurological exam, including dystonia,&#xD;
             ataxia, or any other neurodegenerative disease, including multiple sclerosis or&#xD;
             Parkinson's disease.&#xD;
&#xD;
          3. Significant cognitive impairment or dementia that, in the opinion of the Investigator,&#xD;
             would interfere with participation in the study.&#xD;
&#xD;
          4. An unstable thyroid condition that, per the Investigator's judgment, has not&#xD;
             stabilized over the past 90 days prior to screening. This includes current clinical&#xD;
             history of hypo- or hyperthyroidism, thyrotoxicosis or significant abnormality of&#xD;
             thyroid function testing at Screening.&#xD;
&#xD;
          5. History of, or evidence of psychogenic tremor at Screening.&#xD;
&#xD;
          6. History of anaphylaxis, hypersensitivity reactions (including to any of CAD-1883&#xD;
             excipients), or clinically significant drug allergies.&#xD;
&#xD;
          7. Alkaline phosphatase, aspartate aminotransferase (AST), and/or alanine&#xD;
             aminotransferase (ALT) level &gt;2.0 x upper limit of normal (ULN) at Screening and/or at&#xD;
             Pre-dose.&#xD;
&#xD;
          8. Serum creatinine &gt;120 μmol/L and/or creatinine clearance &lt;60 mL/min (according to&#xD;
             Cockcroft-Gault formula) at Screening and/or at Pre-dose.&#xD;
&#xD;
          9. Total bilirubin &gt;2.0 x ULN at Screening and/or at Pre-dose. Note: isolated bilirubin&#xD;
             &gt;2.0 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is &lt;35%.&#xD;
&#xD;
         10. History of Long QT syndrome and/or QTcF (Fridericia's correction) interval &gt;450 msec&#xD;
             (males) or &gt;470 msec (females) per 12-lead ECG done at Screening.&#xD;
&#xD;
         11. History of Alcohol Use Disorder per Diagnostic Statistical Manual of Mental Disorders,&#xD;
             Fifth Edition (DSM-V) criteria.&#xD;
&#xD;
         12. History of human immunodeficiency virus (HIV) infection or positive screening result&#xD;
             for: HIV 1 or 2 antibodies, hepatitis B surface antigen (HBsAg) or hepatitis B core&#xD;
             antibody (HBcAb), or hepatitis C virus antibody (HCVAb).&#xD;
&#xD;
         13. Has a diagnosis of epilepsy or any history of seizure as an adult, head trauma,&#xD;
             stroke, transient ischemic attack within 1 year prior to Screening, unexplained loss&#xD;
             of consciousness within 1 year prior to Screening, or any lifetime history of&#xD;
             asymptomatic or symptomatic orthostatic hypotension (eg, postural syncope).&#xD;
&#xD;
         14. History of unstable angina, myocardial infarction, chronic heart failure (New York&#xD;
             Heart Association Class 3 or 4), or clinically significant conduction abnormalities&#xD;
             (eg, unstable atrial fibrillation) within 1 year prior to screening.&#xD;
&#xD;
         15. Any major psychiatric disorder that is uncontrolled (for the past 90 days) that, per&#xD;
             the Investigator's judgment, can interfere with any of the study procedures.&#xD;
&#xD;
         16. Subject has cancer, except for the following: basal cell carcinoma or successfully&#xD;
             treated squamous cell carcinoma of the skin; cervical carcinoma in situ; prostatic&#xD;
             carcinoma in situ; or other malignancies curatively treated and with no evidence of&#xD;
             disease recurrence for at least 3 years.&#xD;
&#xD;
         17. Subjects with scheduled surgeries during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cadent Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cadent Investigational Site</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cadent Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cadent Investigational Site</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cadent Investigational Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cadent Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cadent Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <results_first_submitted>June 18, 2021</results_first_submitted>
  <results_first_submitted_qc>June 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2021</results_first_posted>
  <disposition_first_submitted>September 23, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>October 5, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 14, 2020</disposition_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ET</keyword>
  <keyword>Essential Tremor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03688685/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03688685/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open-label Study of CAD-1883</title>
          <description>Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET&#xD;
CAD-1883: Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open-label Study of CAD-1883</title>
          <description>Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET&#xD;
CAD-1883: Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="12.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate the Occurrence and Severity of Treatment Emergent AEs.</title>
        <description>Number of subjects who experienced TEAEs and the severity of those TEAEs.</description>
        <time_frame>Time of signed informed consent until 21 days after first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open-label Study of CAD-1883</title>
            <description>Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET&#xD;
CAD-1883: Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Occurrence and Severity of Treatment Emergent AEs.</title>
          <description>Number of subjects who experienced TEAEs and the severity of those TEAEs.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with at least 1 TAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Mild AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Moderate AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from the time the subject signed the informed consent form until the Follow-Up Visit at Day 21.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open-label Study of CAD-1883</title>
          <description>Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET&#xD;
CAD-1883: Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor must review results communications prior to public release and can embargo communications regarding trial results. At least sixty (60) days prior to submission for publication or presentation, Institution or Investigator shall submit in writing to sponsor for review or comment of any proposed oral or written publication. The sponsor can require changes to the communication and can delay the publication an additional sixty (60) days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cadent Therapeutics (A Novartis Company)</name_or_title>
      <organization>Cadent Therapeutics (A Novartis Company)</organization>
      <phone>1-888-669-6682</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

